FDA approves Parsabiv to treat secondary hyperparathyroidism in patients on hemodialysis Feb. 8, 2017
Repatha cardiovascular outcomes study and cognition function study meet primary endpoints Feb. 3, 2017
Japanese phase III trial of KHK-7580 in secondary hyperparathyroidism meets primary endpoint Feb. 1, 2017
RSS